Maybe clearing their current ongoing SB royalty commitments, to put them in a more favourable position to negotiate sale of SB/BOT to other potential pharmaceutical companies looking to acquire them.
Other pharmaceutical companies wouldn’t want to buy the business with the obligation of paying ongoing royalties on a growing business.
?
Ann: Trading Halt, page-26
-
- There are more pages in this discussion • 183 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.8¢ |
Change
-0.008(1.81%) |
Mkt cap ! $737.5M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.5¢ | 40.0¢ | $2.905M | 7.133M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1400486 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 471154 | 13 |
View Market Depth
| Last trade - 15.11pm 04/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |